Custom Synthesis

Zl3138 View larger

Zl3138

AOB12437

Molarity Calculation Cart®

HOW TO ORDER

$0.00

More info

Novel β-catenin/B-cell lymphoma 9 (BCL9) inhibitor, disrupting the β-catenin/BCL9 protein-protein interaction (PPI) with a Ki of 0.96 μM and without affecting the β-catenin/E-cadherin interaction in living cells, displaying good selectivity for β-catenin/BCL9 over β-catenin/E-cadherin PPIs